Details for Patent: 9,963,459

Which drugs does patent 9,963,459 protect, and when does it expire?

Patent 9,963,459 protects RINVOQ and is included in one NDA.

This patent has forty-four patent family members in thirteen countries.

Summary for Patent: 9,963,459

Title:	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2- ,2,2-Trifluoroethyl)pyrrol and solid state forms thereof
Abstract:	The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-- trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Inventor(s):	Jayanth; Jayanthy (Buffalo, IL), Marroum; Patrick J. (Springfield, VA), Mayer; Peter T. (Libertyville, IL), Mohamed; Mohamed-Eslam F. (Gurnee, IL), Othman; Ahmed A. (Waukegan, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Application Number:	15/857,892
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,963,459
Patent Claim Types: see list of patent claims	Formulation; Compound; Device; Dosage form;

Drugs Protected by US Patent 9,963,459

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-001	Aug 16, 2019		RX	Yes	No			Y

International Family Members for US Patent 9,963,459

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016340167
Australia	2020359635
Australia	2021236570
Australia	2023251492